cut your losses.

  1. 38 Posts.
    lightbulb Created with Sketch. 10
    There is no sugar coating these phase 3 results. They are very disappointing. The HIV antiviral space is crowded with many other promising agents. It would be suprising to see big pharma showing any interest in this drug.

    I have no short or long positions in this stock but would suggest cutting your losses here.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.